NYC shooter's brain will be tested for CTE, other conditions
The story was first reported by The Washington Post.
The medical examiner's tests come after Tamura asked in a three-page note, found in his wallet after the shooting, to be tested for CTE, which is a brain condition experienced by people who have suffered repeated blows to the head, often through contact sports such as football.
Tamura claimed his time playing high school football in California caused him to develop CTE. He also wrote in his note the NFL "knowingly concealed the dangers to our brains to maximize profits. They failed us."
CTE can result in a variety of symptoms, including increased aggression, emotional instability and suicidal thoughts and behavior, according to the Mayo Clinic. It can only be diagnosed posthumously.
As of 2023, the Boston University CTE Center had tested 376 former NFL players for the disease. It found 345 of them (91.7%) suffered from CTE. However, an article revealing that data noted the prevalence among all NFL athletes is unknown because it can only be diagnosed after death and "brain bank samples are subject to selection biases."
"While the most tragic outcomes in individuals with CTE grab headlines, we want to remind people at risk for CTE that those experiences are in the minority," said Dr. Ann McKee, then the director of the BU CTE Center and chief of neuropathology at VA Boston Healthcare System. "Your symptoms, whether or not they are related to CTE, likely can be treated, and you should seek medical care. Our clinical team has had success treating former football players with mid-life mental health and other symptoms."
Chris Nowinski - the CEO of the Concussion Legacy Foundation, which works closely with the Boston University CTE Center - cautioned The Washington Post that even if Tamura is diagnosed with CTE, it wouldn't rule out other factors from having contributed to his actions. Those potential factors include mental illness, genetic disorders and drug use.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
4 hours ago
- Reuters
White House backs away from IVF coverage mandate despite Trump's campaign pledge, Washington Post reports
Aug 3 (Reuters) - The White House has no current plans to mandate insurance coverage for IVF, despite President Donald Trump's campaign promise to expand access to fertility treatments, The Washington post reported on Saturday. Reuters could not immediately verify this report.
The Independent
2 days ago
- The Independent
Medicare and Medicaid move toward covering Ozempic and other weight loss drugs
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients' use of the weight loss drugs, according to a new report. State Medicaid programs and Medicare Part D plans could soon voluntarily choose to cover these drugs for 'weight management,' The Washington Post reports, citing internal documents from the Centers for Medicare and Medicaid. The proposed plan, which has not been finalized, would start in April 2026 for Medicaid and in January 2027 for Medicare. Covering the drugs for weight loss would cost Medicare an estimated $35 billion from 2026 to 2034, the Post reports. However, Medicare is negotiating lower prices for Ozempic and Wegovy in 2027. Currently, the popular drugs can cost upwards of $1,200. These negotiations could save consumers money. Some experts have argued that Medicare prices can serve as a benchmark for private insurance companies and lead to savings, according to the health non-profit Kaiser Family Foundation. More insurers could also be pressured to provide coverage for these medications for weight loss if states opt into the proposed program. Many GLP-1 medications, such as Ozempic, are intended to treat Type 2 diabetes, but in recent years, millions of Americans have turned to them for weight loss management. Medicare covers GLP-1 drugs primarily for Type 2 diabetes treatment, while some private insurance companies already cover the drugs for weight loss. A 2024 Kaiser Foundation survey found that more than half of adults said the cost made it difficult to afford. It's unclear how many states might opt in to the program. Thirteen state Medicaid programs have already chosen to cover GLP-1s for weight loss, the Post reports. Novo Nordisk, the company that makes GLP-1s Ozempic and Wegovy, told the Post they believe 'comprehensive coverage through government and commercial insurance plans is critical to affordable health care and treatment options.' This proposal comes after the Trump administration said in April that Medicaid and Medicare would not cover GLP-1 drugs for weight loss, the Post reports. This ended a previous plan under Joe Biden's administration to cover the drugs. Members of the Trump administration may also be divided on the issue. Centers for Medicare and Medicaid Administration Mehmet Oz has previously called the drugs a 'big help,' while Health and Human Services Secretary Robert F. Kennedy Jr. has raised concerns about the cost of the drugs, the Post reports. A Centers for Medicare and Medicaid spokesperson declined to comment on the proposal. 'All drug coverages undergo a cost-benefit review,' the spokesperson said in a statement. 'CMS does not comment on potential models or coverage.'
The Herald Scotland
2 days ago
- The Herald Scotland
NYC shooter's brain will be tested for CTE, other conditions
"Our office has neuropathology expertise in house and will be examining the brain as part of the additional testing for the complete autopsy," a spokesperson wrote in an email. The story was first reported by The Washington Post. The medical examiner's tests come after Tamura asked in a three-page note, found in his wallet after the shooting, to be tested for CTE, which is a brain condition experienced by people who have suffered repeated blows to the head, often through contact sports such as football. Tamura claimed his time playing high school football in California caused him to develop CTE. He also wrote in his note the NFL "knowingly concealed the dangers to our brains to maximize profits. They failed us." CTE can result in a variety of symptoms, including increased aggression, emotional instability and suicidal thoughts and behavior, according to the Mayo Clinic. It can only be diagnosed posthumously. As of 2023, the Boston University CTE Center had tested 376 former NFL players for the disease. It found 345 of them (91.7%) suffered from CTE. However, an article revealing that data noted the prevalence among all NFL athletes is unknown because it can only be diagnosed after death and "brain bank samples are subject to selection biases." "While the most tragic outcomes in individuals with CTE grab headlines, we want to remind people at risk for CTE that those experiences are in the minority," said Dr. Ann McKee, then the director of the BU CTE Center and chief of neuropathology at VA Boston Healthcare System. "Your symptoms, whether or not they are related to CTE, likely can be treated, and you should seek medical care. Our clinical team has had success treating former football players with mid-life mental health and other symptoms." Chris Nowinski - the CEO of the Concussion Legacy Foundation, which works closely with the Boston University CTE Center - cautioned The Washington Post that even if Tamura is diagnosed with CTE, it wouldn't rule out other factors from having contributed to his actions. Those potential factors include mental illness, genetic disorders and drug use.
